PRO-AZITHROMYCINE TABLET

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE)

Доступна з:

PRO DOC LIMITEE

Код атс:

J01FA10

ІПН (Міжнародна Ім'я):

AZITHROMYCIN

Дозування:

250MG

Фармацевтична форма:

TABLET

Склад:

AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

30/100

Тип рецепту:

Prescription

Терапевтична области:

OTHER MACROLIDES

Огляд продуктів:

Active ingredient group (AIG) number: 0126072001; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2008-09-25

Характеристики продукта

PRODUCT MONOGRAPH
PR
PRO-AZITHROMYCINE
Azithromycin Tablets
250 mg
USP
ANTIBACTERIAL AGENT
PRO DOC LTÉE
2925, boul. Industriel
Laval, Québec
H7L 3W9 DATE OF REVISION:
May 28, 2019
Control number: 227600
_PRO-AZITHROMYCINE Product Monograph _
_Page 2 of 71_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................3
INDICATIONS AND CLINICAL USE
................................................................................3
CONTRAINDICATIONS
......................................................................................................6
WARNINGS AND PRECAUTIONS
....................................................................................6
ADVERSE REACTIONS
....................................................................................................11
DRUG INTERACTIONS
.....................................................................................................18
DOSAGE AND
ADMINISTRATION.................................................................................23
OVERDOSAGE
...................................................................................................................24
ACTION AND CLINICAL PHARMACOLOGY
...............................................................25
STORAGE AND STABILITY
............................................................................................28
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................29
PART II: SCIENTIFIC INFORMATION
................................................................................30
PHARMACEUTICAL INFORMATION
............................................................................30
CLINICAL TRIALS
............................................................................................................31
DETAILED
PHARMACOLOGY.................................................................